Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Background Peptide-based vaccination is a rational option for immunotherapy of prostate cancer. In this first-in-man phase I/II study, we assessed the safety, tolerability and immunological impact of a synthetic long peptide vaccine targeting Ras homolog gene family member C (RhoC) in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Klaus Brasso, Martin Andreas Roder, Hans-Georg Rammensee, Per thor Straten, Cécile Gouttefangeas, Juliane Schuhmacher, Sonja Heidu, Torben Balchen, Jennifer Rebecca Richardson, Camilla Schmeltz, Jesper Sonne, Jonas Schweiker
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001157.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001157.full

Similar Items